Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Neutrolis is raising $40,636,190.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Toby Fox played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Neutrolis
Neutrolis, Inc. is a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cell in our body. Neutrolis lead program targets Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the innate immune system and play an important role in chronic and acute diseases. Based in Cambridge, MA, Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and supported by seasoned business leaders.

To learn more about Neutrolis, visit http://www.neutrolis.com/

Contact:
Toby Fox, Chief Executive Officer
857-930-3397
https://www.linkedin.com/in/toby-fox-43a163166/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved